Log in

Relevant bibliographies by topics / Mycosis - Treatment / Journal articles

To see the other types of publications on this topic, follow the link: Mycosis - Treatment.

Journal articles on the topic 'Mycosis - Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mycosis - Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sakaniya, L. R., and I. M. Korsunskaya. "Foot mycosis: how to help active patients." Meditsinskiy sovet = Medical Council, no. 12 (October 7, 2020): 24–27. http://dx.doi.org/10.21518/2079-701x-2020-12-24-27.

Full text

Abstract:

Mycotic infections of the feet are common fungal infections in our time. According to some reports, about 10% of the world's population suffer from these infections. Men suffer from foot mycosis more often than others. Foot mycosis can manifest itself in three clinical forms: interdigital, plantar and vesiculopapular. Foot mycosis is often combined with onychomycosis or becomes a risk factor for its development. Many diseases, such as diabetes mellitus, vascular diseases, obesity are risk factors for foot mycosis. But what is important is that young and middle-aged people who lead an active lifestyle are at risk. It has long been established that public places such as gyms, swimming pools, baths and saunas are a source of mycotic infections. The internal climatic environment of footwear also has a significant impact on the development of foot mycosis. Closed shoes with high internal temperature and humidity create ideal conditions for dermatophyte growth. That is why people who prefer closed, even cloth shoes, or office workers, who are forced to constantly wear closed shoes, often suffer from foot mycosis and other fungal infections.The main problem in the treatment of foot mycoses is adherence to the prescribed treatment. In our practice, mycotic lesions are more common in people who lead an active lifestyle and are unable to adhere to a long course of therapy. Indeed, the treatment of mycosis often involves a two-week application of some topical antifungal agent. It is optimal to prescribe a single application of terbinafine film forming solution to such patients. This drug ensures the clinical effectiveness of therapy as it keeps antifungi-cidal activity for 13 days from the date of application and high adherence to treatment.

APA, Harvard, Vancouver, ISO, and other styles

2

Yakovlev, A. В. "Issues of stage-by-stage approach to the external therapy of foot skin mycosis." Medical Council, no. 21 (January 20, 2019): 146–51. http://dx.doi.org/10.21518/2079-701x-2018-21-146-151.

Full text

Abstract:

Foot skin mycosis is one of the most topical problems in dermatovenerology due to the extreme prevalence of these diseases. Treatment of foot skin mycoses is the most important step in the prevention of onychomycosis. The tactics and a specific sequence of the external therapy depends on the specific clinical form of mycosis: acute inflammatory forms require the prescription of solutions and gels, subacute forms required creams, chronic forms require adhesive agents. Exudative form of the foot skin mycosis with vesiculation is an indication for the combination therapy.

APA, Harvard, Vancouver, ISO, and other styles

3

Ghitea, Timea Claudia, Simona Bungau, Delia Mirela Tit, Lavinia Purza, Pavel Otrisal, Lotfi Aleya, Gabriela Cioca, Carmen Pantis, and Liviu Lazar. "The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome." Revista de Chimie 71, no. 1 (February 7, 2020): 335–41. http://dx.doi.org/10.37358/rc.20.1.7854.

Full text

Abstract:

This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially evaluated at 10 days after the begining of the treatment (to track mycotic disease evolution in the acute phase), at 60 days (to evaluate the recurrence of mycoses) and at 180 days to track recurrent disease. Most infections were acute (77.78%), the chronic ones representing only 5.56% of cases. There were also 12 cases with recurrent infections (16.67%), out of which 6 cases (8.33%) had previously shown resistance to Nystatin. In the 72 cases there was a sensitivity of 100.00% for oregano oil and Ketaconazolum, insignificantly higher than for Myconazolum (97.22%, p=0.157), but significantly higher than for Clotrimazolum and Nystatinum (94.44%, p=0.0437), Variconazole and Fluconazole (88.89%, p=0.0038) and Itraconazole (86.11%, p=0.0011). The results of this study showed an increased efficiency of oregano oil on the symptomatic and paraclinical improvement of mycotic infections in the study, both on short term and on long term, which was completed with high tolerability.

APA, Harvard, Vancouver, ISO, and other styles

4

Vdovina, L. V., N. V. Tiunova, S. M. Tolmacheva, and I. N. Usmanova. "Geotrlchous stomatitis in the dental practice." Endodontics Today 18, no. 2 (August 1, 2020): 68–72. http://dx.doi.org/10.36377/1683-2981-2020-18-2-68-72.

Full text

Abstract:

A literature review was conducted on rare mycoses of the oral mucosa in patients with immunode^ciency conditions and hematologic malignant diseases, in particular, etiopathogenetic aspects, clinical features and an approach to the treatment of rare oral mycosis - geotrlchous stomatitis were examined.

APA, Harvard, Vancouver, ISO, and other styles

5

Mizernitsky, Yu L., S. E. Dyakova, M. V. Kostyuchenko, G. A. Klyasova, A. A. Malchikova, and M. P. Afanasyeva. "Allergic bronchopulmonary mycosis in a child caused by Paecilomyces lilacinus." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 64, no. 2 (May 15, 2019): 102–9. http://dx.doi.org/10.21508/1027-4065-2019-64-2-102-109.

Full text

Abstract:

The article discusses the problem of allergic bronchopulmonary mycoses, which occur in children much more often than they are diagnosed. Their treatment is a challenge, and the prognosis is very problematic. In addition to the most frequent cause of Aspergillus, allergic bronchopulmonary mycoses can be caused by various fungi. The clinical example demonstrates the difficulty of diagnosing and treating a child with allergic bronchopulmonary mycosis caused by a rare type of filamentous fungi Paecilomyces lilacinus.

APA, Harvard, Vancouver, ISO, and other styles

6

Shurygin, A. A., A. E. Shirinkina, E. A. Makarova, A. V. Sergeev, and I. A. Marusich. "Clinical case of invasive candidiasis in phthisiatrician’s practice." Perm Medical Journal 36, no. 6 (January 30, 2020): 83–94. http://dx.doi.org/10.17816/pmj36683-94.

Full text

Abstract:

The paper presents a case of generalized candidomycosis in a 67-year old woman. Literature data regarding the cases of respiratory mycoses and candida sepsis are summarized. This case is interesting from the point of view of difficulty of differential diagnosis in patients with respiratory mycosis and tuberculosis, choice of adequate treatment.

APA, Harvard, Vancouver, ISO, and other styles

7

Edakuni, Setsuo, Ryozo Hayasida, Akihiro Hayashi, Akira Adachi, Yutaka Nishimura, Teruo Kakegawa, and Shinzo Edakuni. "Surgical Treatment of Pulmonary Mycosis." Journal of the Japanese Association for Chest Surgery 4, no. 3 (1990): 318–24. http://dx.doi.org/10.2995/jacsurg1987.4.318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Acikgoz, Gurol, Yildiray Yeniay, Ercan Caliskan, and Osman Kose. "Bexarotene Treatment for Mycosis Fungoides." Gulhane Medical Journal 57, no. 4 (2015): 343. http://dx.doi.org/10.5455/gulhane.159145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

CHURCH, SALLY, G. WYN-JONES, A. H. PARKS, and H. E. RITCHIE. "Treatment of guttural pouch mycosis." Equine Veterinary Journal 18, no. 5 (September 1986): 362–65. http://dx.doi.org/10.1111/j.2042-3306.1986.tb03654.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Freiman, Anatoli, and Denis Sasseville. "Treatment of Mycosis Fungoides: Overview." Journal of Cutaneous Medicine and Surgery 10, no. 5 (September 2006): 228–33. http://dx.doi.org/10.2310/7750.2006.00051.

Full text

Abstract:

Background: Mycosis fungoides (MF) is the most common clinicopathologic subtype of primary cutaneous T-cell lymphoma. Objective: The therapy of MF is highlighted in this overview. Results and Conclusions: Skin-directed MF therapies include topical corticosteroids, nitrogen mustard, carmustine (BCNU), topical bexarotene gel, imiquimod cream, radiotherapy, total skin electron beam therapy, and phototherapy. Systemic therapies include extracorporeal photopheresis, interferon, oral bexarotene, denileukin diftitox, monoclonal antibodies and cytokine therapy, and other systemic chemotherapy. Finally, some investigative therapeutic modalities are presented.

APA, Harvard, Vancouver, ISO, and other styles

11

Jaque, Alejandra, Alexandra Mereniuk, Shachar Sade, Perla Lansang, Kevin Imrie, and Neil H. Shear. "Eosinophils in the skin—a red herring masking lymphoma: a case series." SAGE Open Medical Case Reports 6 (January 2018): 2050313X1877312. http://dx.doi.org/10.1177/2050313x18773127.

Full text

Abstract:

Eosinophilia, both peripheral and in cutaneous tissue, is not a typical finding in mycosis fungoides; in fact, when faced with a lymphoeosinophilic infiltrate, mycosis fungoides is often not part of initial differential considerations. However, eosinophilia has been described in certain subtypes of mycosis fungoides, namely, in folliculotropic mycosis fungoides. We describe three challenging cases of folliculotropic mycosis fungoides presenting with varied clinical morphologies and a dense lymphoeosinophilic infiltrate and/or severe hypereosinophilia that obscured the final diagnosis for years. Only after treatment of the eosinophilia were the underlying atypical lymphocytes more apparent on histology and a correct diagnosis made. Thus, when characteristic features of mycosis fungoides are subtle, eosinophils can act as a red herring in terms of clinico-pathologic correlation and may prevent early and accurate diagnosis of mycosis fungoides. We suggest that further studies are needed to evaluate whether treatments to reduce eosinophilia, once other causes have been excluded, may help clear the confounding reactive inflammatory infiltrate and facilitate the diagnosis of mycosis fungoides.

APA, Harvard, Vancouver, ISO, and other styles

12

Khadka, Sundar, Jeevan Bahadur Sherchand, Dinesh Binod Pokharel, Bharat Mani Pokhrel, Shyam Kumar Mishra, Subhash Dhital, and Basista Rijal. "Clinicomycological Characterization of Superficial Mycoses from a Tertiary Care Hospital in Nepal." Dermatology Research and Practice 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/9509705.

Full text

Abstract:

Background. Superficial mycosis is a common fungal infection worldwide, mainly caused by dermatophytes. However, the prevalence of species varies geographically. In addition, fungal treatment is best guided according to species isolated. This study was carried out to determine the clinical as well as mycological profile of superficial mycoses in a tertiary care hospital, Nepal.Methods. This was a prospective case-control laboratory based study conducted over a period of six months from January to June 2014 at Tribhuvan University Teaching Hospital, Nepal. A total of 200 specimens were collected from the patients suspected of superficial mycoses. The specimens were macroscopically as well as microscopically examined. The growth was observed up to 4 weeks.Results.Out of total 200 specimens from the patients suspected of superficial mycoses, tinea corporis 50 (25%) was most common clinical types. KOH mount was positive in 89 (44.5%) and culture was positive in 111 (55.5%).Trichophyton mentagrophytes44 (39.6%) was the most common isolate.Conclusions.The diagnostic yields of KOH mount and culture were found to be complementary to each other. Thus both the methods added with clinical findings are equally important to establish superficial mycosis.

APA, Harvard, Vancouver, ISO, and other styles

13

García Carnero, Laura, Nancy Lozoya Pérez, Sandra González Hernández, and José Martínez Álvarez. "Immunity and Treatment of Sporotrichosis." Journal of Fungi 4, no. 3 (August 20, 2018): 100. http://dx.doi.org/10.3390/jof4030100.

Full text

Abstract:

Species of the Sporothrix complex are the etiological agents of sporotrichosis, an important subcutaneous mycosis with several clinical forms and an increasing incidence around the world that affects humans and other mammals. The immunological mechanisms involved in the prevention and control of this mycosis are not entirely understood. Many reports have suggested that cell-mediated immunity has an essential role in the development of the disease, being the primary response controlling it, while only recent data supports that the humoral response is essential for the appropriate control. This mycosis is a challenge for diagnosis since the culture and isolation of the organism are time-consuming and complicated; reasons that have led to the study of fungus antigenic molecules capable of generating a detectable humoral response. The treatment for this disease includes the use of several antifungal drugs like itraconazole, amphotericin B, caspofungin, fluconazole, and the combination between them among others such as the extract of Vismia guianensis.

APA, Harvard, Vancouver, ISO, and other styles

14

Rozaliyani, Anna, Anwar Jusuf, Priyanti ZS, Erlina Burhan, Diah Handayani, Henie Widowati, Satria Pratama, and Findra Setianingrum. "Pulmonary Mycoses in Indonesia: Current Situations and Future Challenges." Jurnal Respirologi Indonesia 39, no. 3 (July 3, 2019): 210–14. http://dx.doi.org/10.36497/jri.v39i3.69.

Full text

Abstract:

Cases of pulmonary mycosis or pulmonary fungal diseases continues to increase in frequency along with the expanding population with impaired immune systems, including patients with pre-existing pulmonary diseases. Changing profile of underlying diseases might cause altering diseases profile as well. In previous decades, Pneumocystis pneumonia was the most common pulmonary mycosis in HIV-infected patients. As the increasing number of TB cases, pulmonary malignancy, chronic obstructive pulmonary disease (COPD) and certain chronic diseases, other pulmonary mycoses also increase such as chronic pulmonary aspergillosis, cryptococcosis, histoplasmosis, and other filamentous fungal infection. Furthermore, the airborne fungal particles of Aspergillus and other fungi could seriously worsen asthma or allergic respiratory diseases. In low- and middle-income countries, including Indonesia, lack of diagnostic facilities may lead to inadequate treatment. It will contribute to poor clinical outcomes with high mortality rates. The awareness among clinicians and other health workers of this epidemiology changes is the important step in early diagnosis and better managemenet of pulmonary mycosis in the future. (J Respir Indo. 2019; 39(3): 210-4)

APA, Harvard, Vancouver, ISO, and other styles

15

Kumar, Saurabh, Iram Shaifali, and Shalini Chandra. "A study on rapid diagnosis (by PCR) and cost-effective treatment of pulmonary mycosis." International Journal of Research in Medical Sciences 6, no. 6 (May 25, 2018): 1938. http://dx.doi.org/10.18203/2320-6012.ijrms20182041.

Full text

Abstract:

Background: Incidence of Pulmonary Mycosis is rampantly growing in critically ill patients. This study was designed to comparatively evaluate conventional and molecular method-Polymerase Chain Reaction (PCR) for detecting Candida and Aspergillus species in Brocho-Alveolar Lavage (BAL) samples and secondarily to find out the Cost-Effective treatment for Pulmonary Mycosis.Methods: In this study 100 BAL-specimens were collected from patients suspected of Pulmonary Mycosis. These samples were examined for Aspergillus and Candida species by preparation of wet smear using potassium hydroxide, Gram staining, Culture media and Polymerase Chain Reaction (PCR). For Cost-Effectiveness analysis(CEA), a decision tree model was constructed for Anidulafungin and Fluconazole The probability of treatment success and mortality rate were extracted from published Randomized Control Trials. Incremental Cost Effectiveness Ratio (ICER) was calculated.Results: Out of 100 samples, 22 were found to be positive for mycotic infections, 9 were detected as Candida and 13 as Aspergillus. On comparing with KOH and Culture, it was observed that all KOH positive and all Culture positive fungal infections were PCR positive. In no cases PCR negative was identified either culture or KOH positive. This establishes the superiority of PCR over conventional diagnostic methods. Anidulafungin was associated with an Incremental Cost Effectiveness Ratio (ICER) of INR 1,13,217 per LY saved, which was below the implicit ICER threshold for India.Conclusions: PCR is a novel molecular method for early and definitive diagnosis of fungal infection and Aidulafungin appears to be the cost-effective drug for treatment of Pulmonary Mycosis.

APA, Harvard, Vancouver, ISO, and other styles

16

Fujimura, Taku, Kayo Tanita, Yota Sato, Yumi Kambayashi, Sadanori Furudate, Akira Tsukada, Akira Hashimoto, and Setsuya Aiba. "Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy." Case Reports in Oncology 11, no. 1 (January 16, 2018): 29–32. http://dx.doi.org/10.1159/000486278.

Full text

Abstract:

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

APA, Harvard, Vancouver, ISO, and other styles

17

Tokimatsu, Issei. "Antifungal Treatment for Deep Seated Mycosis." Nippon Ishinkin Gakkai Zasshi 49, no. 2 (2008): 137–41. http://dx.doi.org/10.3314/jjmm.49.137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Shipman, AlexaRose, and Julia Scarisbrick. "New treatment options for mycosis fungoides." Indian Journal of Dermatology 61, no. 1 (2016): 119. http://dx.doi.org/10.4103/0019-5154.174085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

ZETTERGREN, L., and B. SJÖSTRÖM. "Disseminated Mycosis after Treatment with Antibiotics." Acta Medica Scandinavica 147, no. 3 (April 24, 2009): 203–12. http://dx.doi.org/10.1111/j.0954-6820.1954.tb12233.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

FITZPATRICK, JAMES E., and J. RAMSEY MELLETTE. "Treatment of Mycosis Fungoides with Isotretinoin." Journal of Dermatologic Surgery and Oncology 12, no. 6 (June 1986): 626–29. http://dx.doi.org/10.1111/j.1524-4725.1986.tb01961.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Peck, Joshua R., Michael P. Frank, and Lawrence R. Peck. "Was Treatment the Trigger? Mycosis Fungoides." American Journal of Medicine 126, no. 12 (December 2013): 1048–49. http://dx.doi.org/10.1016/j.amjmed.2013.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Porntharukcharoen, Saneerat, Suthinee Rutnin, and Natta Rajatanavin. "Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature." Case Reports in Dermatology 9, no. 3 (November 27, 2017): 243–48. http://dx.doi.org/10.1159/000484472.

Full text

Abstract:

Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Both large-cell transformed mycosis fungoides and mycosis fungoides bullosa are rare presentations and predict unfavorable prognosis. We report the case of a 61-year-old woman who presented with generalized erythematous scaly annular plaques, and histopathology confirmed the diagnosis of mycosis fungoides. She was treated with various conventional therapies but only achieved partial response and always relapsed after discontinuation of treatment. Her last treatment was combined chemotherapy (CHOP regimen) followed by romidepsin. However, 1 month after the last cycle of romidepsin, she developed multiple ulcerative masses and nodules. Skin biopsy was compatible with CD30+ large cell transformation, and she was treated with a new combination of chemotherapy (ifosfamide, carboplatin, etoposide). One day after receiving chemotherapy, multiple tense bullae on normal-appearing skin and mycosis fungoid plaques erupted. A histological study demonstrated subepidermal blistering with epidermotropism of atypical lymphocytes. Direct immunofluorescence study was negative. The results confirmed the diagnosis of mycosis fungoides bullosa. We present the first reported case of large-cell transformed mycosis fungoides coexisting with mycosis fungoides bullosa.

APA, Harvard, Vancouver, ISO, and other styles

23

Pozsgai, Melánia, Rolland Gyulai, Csaba Gyömörei, and Zsuzsanna Lengyel. "Skin directed treatment of cutaneous T-cell lymphomas, case report." Bőrgyógyászati és Venerológiai Szemle 96, no. 5 (October 21, 2020): 212–18. http://dx.doi.org/10.7188/bvsz.2020.96.5.1.

Full text

Abstract:

Cutaneous T-cell lymphomas are rare diseases with significant differences in their clinical course and prognosis. The choice of treatment basically depends on the stage, in the early stages of the disease only skin directed treatment is recommended. With most of the treatment modalities, complete cure is not possible, only long-term remission can be achieved. The authors report the case of a 52-year-old female patient who developed extensive annular, erythematous, infiltrated plaques in the spring of 2019. Histological examination confirmed mycosis fungoides, imaging did not show lymph node or other organ involvement. Given the disease (stage IB), PUVA treatment was initiated. After a total of 21 sessions of phototherapy from September 2019, the patient underwent complete remission. The authors provide a detailed review of skin directed treatment options for mycosis fungoides based on current international recommendations.

APA, Harvard, Vancouver, ISO, and other styles

24

Nagy, Linda, Enikő Szép, Enikő Telegdy, Miklós Egyed, and Zita Battyáni. "Early stage mycosis fungoides responsive to acitretin monotreatment." Bőrgyógyászati és Venerológiai Szemle 96, no. 5 (October 21, 2020): 219–22. http://dx.doi.org/10.7188/bvsz.2020.96.5.2.

Full text

Abstract:

The authors present a case of a 36 year- old male patients, with St. IB mycosis fungoides with extensive skin symptoms. They decided acitretin monotherapy, as first line treatment. The patient responded well, and became permanently asymptomatic. The authors provide a brief literature review of the role of acitretin in the treatment of mycosis fungoides.

APA, Harvard, Vancouver, ISO, and other styles

25

GARVEY, MARY, M. BLACK, and FRANCES LAWLOR. "(55) Erythrodermic mycosis fungoides: diagnosis and treatment." British Journal of Dermatology 125, s38 (July 1991): 78–79. http://dx.doi.org/10.1111/j.1365-2133.1991.tb05524.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kujath, P., and K. Lerch. "Secondary mycosis in surgery: Treatment with fluconazole." Infection 17, no. 2 (March 1989): 111–17. http://dx.doi.org/10.1007/bf01646895.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Beygi, Sara, Sebastian Fernandez-Pol, George Duran, Erica B. Wang, Henning Stehr, James L. Zehnder, Nirasha Ramchurren, et al. "Pembrolizumab in mycosis fungoides with PD-L1 structural variants." Blood Advances 5, no. 3 (February 3, 2021): 771–74. http://dx.doi.org/10.1182/bloodadvances.2020002371.

Full text

Abstract:

Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

28

Laus, F., E. Paggi, M. Cerquetella, D. Spaziante, A. Spaterna, and B. Tesei. "Guttural pouch mycosis in a donkey (Equus asinus): a case report." Veterinární Medicína 55, No. 11 (December 1, 2010): 561–65. http://dx.doi.org/10.17221/3011-vetmed.

Full text

Abstract:

Guttural pouch mycosis is an emergency disease of the upper respiratory tract in equine species. In the present report a case of guttural pouch mycosis in a female, seven year-old pregnant donkey is described. A serious dyspnea which necessitated tracheotomy and preceding epistaxis was the most important clinical feature of guttural pouch mycosis in the donkey. A full and rapid effectiveness of the topical therapy, the protocol for which is described, is the main distinguishing feature with regard to treatment. In the Authors' knowledge a detailed description of clinical features, treatment and follow up of guttural pouch mycosis in a donkey is not available in the scientific literature. The anatomical and physiological peculiarity of donkeys could explain some of the differences with horses in clinical presentation and therapeutic management.

APA, Harvard, Vancouver, ISO, and other styles

29

Yakovlev, A. B. "Efficacy and safety of Exifin^® in treatment of mycoses of skin and nail plates." Medical alphabet 2, no. 26 (November 19, 2019): 54–61. http://dx.doi.org/10.33667/2078-5631-2019-2-26(401)-54-61.

Full text

Abstract:

The mycoses of the skin and nail plates of the feet are the second most common in the human population after pyoderma, and are the fact of a significant decrease in the quality of life of patients. In the present multicenter observational study, the results of the evaluation of the quality of life of 1 674 patients before and after successful treatment of mycosis of the skin and nails with the use of the drug Exifine®: showing a clear correlation between successful eradication of the pathogen and to improve the quality of life of the patient in all age groups. In no case was there any mention of adverse reactions to either the external or the systemic dosage form of the drug.

APA, Harvard, Vancouver, ISO, and other styles

30

Atilla, Erden, Pinar Ataca, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Bengu Nisa Akay, Hatice Sanli, et al. "Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides." Blood 126, no. 23 (December 3, 2015): 5062. http://dx.doi.org/10.1182/blood.v126.23.5062.5062.

Full text

Abstract:

Abstract Backround: The treatment of mycosis fungoides (MF) is determined by disease extent, prognostic factors and patient characteristics. Extracorporeal Photopheresis (ECP) was approved by the US Food and Drug Administiration for the palliative treatment of mycosis fungoides since 1988. Herein, we present our MF patients who have received ECP. Patients and Methods: We retrospectively included 50 MF patients who have diagnosed at our center. ECP was given empirically in cycles of 2 consecutive days in every 2 to 4 weeks at any time during their follow-up. Results: The patient characteristics is shown in table. Previous lines of treatments were; topical retinoids (bexarotene), topical corticosteroids, phototherapy (PUVA), Narrowband ultraviolet B light (NBUVB), Interferons, Metotrexate (MTX), CHOP (cyclophosphamide, daunorubicin, vincristine, prednisolone). ECP is combined with gemcitabine, PUVA, MTX, Bexaroten, IFN or Vorinostat. The overall response rate (ORR) was 54% with 30% complete response rate (CRR). 10/15 complete responders (67%) had stage 3-4 disease at diagnosis and 7/15 (47%) had received ≥ 3 lines of treatment prior to ECP. 18 patients (36%) had progressive disease after ECP while 3 patients (6%) were refractory and underwent allogeneic stem cell transplantation. The few adverse events of ECP included in 8 patients (16%) as catheter-related infection, headache, fever, chills and nausea. The OS was 68 months. Conclusion: ECP is a favorable treatment option for suitable patients in MF with high ORR and low risk of adverse events. Presenter has relevant financial relationship(s) to disclose: No. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

31

AKARAPHANTH, R. "Hypopigmented mycosis fungoides: Treatment with UVB and PUVA." Journal of the European Academy of Dermatology and Venereology 11 (September 1998): S320. http://dx.doi.org/10.1016/s0926-9959(98)95812-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Silver, Stephen E. "Topical mechlorethamine in the treatment of mycosis fungoides." Journal of the American Academy of Dermatology 27, no. 5 (November 1992): 786. http://dx.doi.org/10.1016/s0190-9622(08)80237-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kaufman, A. E., K. Patel, K. Goyal, D. O'Leary, N. Rubin, D. Pearson, K. Bohjanen, and A. Goyal. "Mycosis fungoides: developments in incidence, treatment and survival." Journal of the European Academy of Dermatology and Venereology 34, no. 10 (May 24, 2020): 2288–94. http://dx.doi.org/10.1111/jdv.16325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Drews, Reed E. "Emerging Treatment Options for Advanced-Stage Mycosis Fungoides." Journal of Clinical Oncology 30, no. 33 (November 20, 2012): 4064–70. http://dx.doi.org/10.1200/jco.2012.44.5650.

Full text

Abstract:

A 72-year-old man with a 3-year history of hypersensitivity skin reaction managed with topical steroids and ultraviolet B (UVB) radiation develops skin tumors chiefly involving his face. After a diagnosis of stage IIB mycosis fungoides (MF), he begins oral low-dose weekly methotrexate with partial response lasting 5 months. Subsequently, he receives six cycles of weekly gemcitabine and achieves a partial response with resolution of skin tumors but persistence of scattered patches and plaques ( Fig 1 ). He begins daily bexarotene and interferon alfa (IFN-α) three times per week while continuing topical steroids. When scattered patches and plaques progress 7 months later, UVB radiation is added to his regimen. His disease remains well controlled until 17 months later, when he develops pneumonia complicated by pericarditis, requiring discontinuation of IFN-α. Over the next year, he continues bexarotene maintenance therapy and topical steroids but requires localized radiation therapy to isolated patch and tumor lesions. When patch lesions become more extensive, he receives total-skin electron beam therapy (TSEBT). Nearly 4 years after diagnosis of stage IIB MF and 5 months after completion of TSEBT, two tumor lesions redevelop on his face and scalp. The scalp tumor has overlying epidermal change with ulceration; the face tumor is subdermal with minimal overlying epidermal change and obstructs the right external auditory meatus ( Fig 1 D). You consider management options.

APA, Harvard, Vancouver, ISO, and other styles

35

Pabsch, Heike, Arno Rtten, Andrea von Stemm, Wilhelm Meigel, Christian A. Sander, and Jrg Schaller. "Treatment of childhood mycosis fungoides with topical PUVA." Journal of the American Academy of Dermatology 47, no. 4 (October 2002): 557–61. http://dx.doi.org/10.1067/mjd.2002.124073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

KUME, H. "Problems for diagnosis and treatment of visceral mycosis." Mycotoxins 1989, no. 29 (1989): 1–4. http://dx.doi.org/10.2520/myco1975.1989.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ariffin, N., and M. Khorshid. "Treatment of mycosis fungoides with imiquimod 5% cream." Clinical and Experimental Dermatology 31, no. 6 (November 2006): 822–23. http://dx.doi.org/10.1111/j.1365-2230.2006.02208.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Breneman, Debra L., Ann Like Nartker, Elaine A. Ballman, Jane M. Pruemer, Renee F. Blumsack, Mindy Davis, and John C. Brenemann. "Topical mechlorethamine in the treatment of mycosis fungoides." Journal of the American Academy of Dermatology 25, no. 6 (December 1991): 1059–64. http://dx.doi.org/10.1016/0190-9622(91)70307-n.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chaidemenos, G., T. Spiliopoulos, E. Balaskas, and G. Kontochristopoulos. "LB970 Dermoscopy during treatment of early Mycosis Fungoides." Journal of Investigative Dermatology 140, no. 7 (July 2020): B17. http://dx.doi.org/10.1016/j.jid.2020.05.069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Duffy, Robert, Tara Jennings, Saritha Kartan, Andrew Song, Wenyin Shi, Pierluigi Porcu, Onder Alpdogan, and Joya Sahu. "Special Considerations in the Treatment of Mycosis Fungoides." American Journal of Clinical Dermatology 20, no. 4 (April 16, 2019): 571–78. http://dx.doi.org/10.1007/s40257-019-00431-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Deaver, Darcie, Ashley Cauthen, George Cohen, Lubomir Sokol, and Frank Glass. "Excimer laser in the treatment of mycosis fungoides." Journal of the American Academy of Dermatology 70, no. 6 (June 2014): 1058–60. http://dx.doi.org/10.1016/j.jaad.2014.01.915.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Schmidt, Adriana, Jason Robbins, and John Zic. "Transformed mycosis fungoides developing after treatment with alefacept." Journal of the American Academy of Dermatology 53, no. 2 (August 2005): 355–56. http://dx.doi.org/10.1016/j.jaad.2005.02.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Karanina, V. D. "Medical treatment of guttural pouch my-cosis in horses." International bulletin of Veterinary Medicine 3 (2020): 9–14. http://dx.doi.org/10.17238/issn2072-2419.2020.3.9.

Full text

Abstract:

Mycosis of the air-bearing SAC is an infectious chronic disease of horses, charac-terized by nasal discharge and bleeding, var-ious neuropathies; and the main danger of which is the possibility of lethal epistaxis. Fungi of the genus Aspergillus enter the cav-ity of the bags with inhaled air and settle on the mucosa, damaging the large arterial ves-sels (internal and external carotid arteries) and nerves (facial, lingopharyngeal, vagus and hypoglossal cranial nerves) running along its surface. The recommended treat-ment is surgery on the carotid arteries. How-ever, in a stable environment, conservative treatment is safer. This paper provides an overview of effective drug therapy regimens for mycosis of the equine air SAC. For successful elimination of the patho-gen, it is necessary to occlude the affected vessels to limit the nutrition of the fungus. However, such surgical techniques are ac-companied by a huge risk, require expensive supplies, a sterile operating room and a high-ly qualified veterinarian. The effectiveness of conservative treat-ment consists of two components: mechani-cal action on the fungus in order to separate it and antimycotic therapy, taking into ac-count the sensitivity of the species to the antibiotic. Daily flushing of the air bag with an endoscope at the site of the lesion can soften the diphtheria membrane, which will later allow it to be separated from the wall using biopsy forceps or a cytological brush. The relevance of the work is that it is easier and safer to carry out conservative treatment of mycosis of the air bag in sta-bles. The purpose of this work is to review effective treatment regimens for mycosis of the equine air SAC without surgical inter-vention. So, we can call the treatment regi-men Itraconazole priority, because this drug has been widely studied on horses and has a high activity to fungi of the genus Aspergil-lus.

APA, Harvard, Vancouver, ISO, and other styles

44

Upadhyay, Kavita. "Mucor Mycosis in COVID-19: Case Reports." Journal of Advanced Research in Medicine 07, no. 03 (December 22, 2020): 20–23. http://dx.doi.org/10.24321/2349.7181.202016.

Full text

Abstract:

Coronavirus infections are associated with a wide range of bacterial and fungal co-infections. Use of steroids, monoclonal antibodies and broad spectrum antibiotics along with underlying pathogenesis may alter body homeostasis and exacerbate preexisting fungal disease. We report the cases with COVID-19 infection, which, after the course of the treatment, presented with various forms of mucormycosis infection.

APA, Harvard, Vancouver, ISO, and other styles

45

Atalla, Angelo, Abrahão Elias Hallack Neto, Denise Bittencourt Siqueira, and Gabriela Cumani Toledo. "Allogeneic hematopoietic stem cell transplantation in mycosis fungoides." Anais Brasileiros de Dermatologia 88, no. 6 suppl 1 (December 2013): 216–19. http://dx.doi.org/10.1590/abd1806-4841.20132365.

Full text

Abstract:

Mycosis Fungoides is typically an indolent disease in early stages. However, approximately 30% of patients have advanced staged disease at presentation and 20% will develop it at some time. These patients have a poorer prognosis with a median survival of 2-4 years. The only curative option for mycosis fungoides may be hematopoietic allogeneic stem cell transplantation. We report the case of a patient with mycosis fungoides in an advanced stage (IIB), refractory to treatment options. She underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The patient remains in complete remission nineteen months after allo-HSCT. Allogeneic transplantation can alter the natural history of mycosis fungoides and should be considered in patients who have refractory disease or short-lived responses with standard therapies.

APA, Harvard, Vancouver, ISO, and other styles

46

Rojas Rondón, Irene, Lázaro Vigoa Aranguren, Maritza Miqueli Rodríguez, María de Lourdes Guzmán Martínez, and Manuel Alejandro Múzquiz Jiménez. "Fungoide Mycosis. Case report." Bionatura 6, no. 1 (February 15, 2021): 1608–11. http://dx.doi.org/10.21931/rb/2021.06.01.25.

Full text

Abstract:

To report the case of a 63-years-old female referred to the Oculoplastic Eyelid and Orbit Department of the ICO "Ramón Pando Ferrer" for two lesions in the left upper eyelid, the biggest one, a 20 mm nodule with a central ulcer full of debris and discharge. It was treated with antibiotics without improvement; a biopsy was carried out with a preliminary report of Mycosis Fungoides. A similar lesion appeared on the lower eyelid after surgery and was treated with perilesional HeberFERON injections, disappearing after three weeks. The final histopathology analysis revealed a Non-Hodgkin skin lymphoma with a high malignancy grade. Conclusions: Diagnosing Mycosis fungoides is difficult in early stages or atypical presentations. It's essential to know this disease and its stages to set it apart from entities with similar characteristics, aiming for an early diagnosis, treatment, and proper follow-up.

APA, Harvard, Vancouver, ISO, and other styles

47

Gabriel, Iwona. "‘Acridines’ as New Horizons in Antifungal Treatment." Molecules 25, no. 7 (March 25, 2020): 1480. http://dx.doi.org/10.3390/molecules25071480.

Full text

Abstract:

Frequent fungal infections in immunocompromised patients and mortality due to invasive mycosis are important clinical problems. Opportunistic pathogenic Candida species remain one of the leading causes of systemic mycosis worldwide. The repertoire of antifungal chemotherapeutic agents is very limited. Although new antifungal drugs such as lanosterol 14α-demethylase and β-glucan synthase inhibitors have been introduced into clinical practice, the development of multidrug resistance has become increasingly significant. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets to the conventional ones currently used. Among them, many compounds containing an acridine scaffold have been synthesized and tested. In this review, the applicability of acridines and their functional analogues acridones as antifungal agents is described. Acridine derivatives usage in photoantifungal chemotherapy, interactions with fungal transporters resulting in modulation of efflux/influx pumps and the effect of acridine derivatives on fungal topoisomerases are discussed. This article explores new perspectives on the mechanisms of antifungal acridine-peptide conjugates and acridine-based hybrid molecules to effectively combat fungal infections.

APA, Harvard, Vancouver, ISO, and other styles

48

Heyman, Benjamin, Chris R. Kelsey, and Anne Beaven. "Durable Control of Mycosis Fungoides after Sepsis: “Coley’s Toxin?” Case Report and Review of the Literature." Case Reports in Hematology 2019 (August 4, 2019): 1–4. http://dx.doi.org/10.1155/2019/1507014.

Full text

Abstract:

Mycosis fungoides, along with Sezary syndrome, is the most common subtype of cutaneous T-cell lymphoma. In this report, we present a patient with advanced-stage mycosis fungoides, who after successful treatment of methicillin-resistantStaphylococcus aureusbacteremia had prolonged disease control off systemic therapy. While this may have been due to single-agent gemcitabine, which can result in long remission, we hypothesize that our patient’s durable response was in part due to the immune response elicited after treatment of her severe infection.

APA, Harvard, Vancouver, ISO, and other styles

49

Di Busroh, Ismid, M. Nurolim Mallapasi, and Tarmizi Hakim. "Surgery for Pulmonary Mycosis." Asian Cardiovascular and Thoracic Annals 5, no. 2 (June 1997): 104–6. http://dx.doi.org/10.1177/021849239700500209.

Full text

Abstract:

We reviewed 739 cases of surgery for pulmonary infection between 1970 and 1990 at the Persahabatan Hospital, Jakarta. In 32 cases (13.61%) surgery was performed for pulmonary mycosis. There were 20 males and 12 females; the majority were between 31 and 50 years of age and all were symptomatic. Primary mycosis infection was found in only 1 case (3%) with a diagnosis of coccidioidomycosis; the other 31 patients had aspergillosis secondary to tuberculosis. Pneumonectomy was performed in 2 cases (6%), lobectomy in 28 cases (88%), and cavernoplasty in 2 cases (6%). Four operations were performed on an emergency basis, 15 were regarded as semi-emergencies, and 13 were carried out electively. Postoperative complications consisted of 2 cases of bronchopleural fistula, one of which was self-healing and the other needed a muscle plombage. There was 1 death (mortality 3%) from septic shock 3 weeks after the operation. The low mortality and morbidity support a surgical approach to the treatment of pulmonary mycosis in symptomatic patients.

APA, Harvard, Vancouver, ISO, and other styles

50

Elad, Daniel. "Therapy of Non-Dermatophytic Mycoses in Animals." Journal of Fungi 4, no. 4 (October 30, 2018): 120. http://dx.doi.org/10.3390/jof4040120.

Full text

Abstract:

This review focuses on aspects of antimycotic therapy specific to veterinary medicine. In the first part, drug availability, limited mostly by economic consideration but also by clinical applicability and specific adverse effects, is described for polyenes, 5 fluorocytosine, azoles, echinocandins and terbinafine. In the second part, current knowledge and experience in the treatment of selected fungal infections are overviewed. These mycoses include disseminated mold infections in small animals (dogs and cats) and avian species, upper respiratory tract infections of small animals (sino-nasal and sino-orbital aspergillosis) and horses (guttural pouch mycosis), eumycetoma, infections caused by dimorphic fungi, (blastomycosis, histoplasmosis, coccidioidomycosis, paracoccidioidomycosis and sporothrichosis) and by yeasts and yeast-like microorganism (Cryptococcus spp. and Malassezia pachydermatis).

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!